Arvinas, Inc.
ARVN Healthcare Biotechnology
Arvinas, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $262.6 million, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 1,014.7%, EPS grew 410.7%, free cash flow grew 49.8% and total debt fell 40.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ARVN
Arvinas, Inc. (ARVN) EV/Sales
As of 12 October 2026, Arvinas, Inc. (ARVN) trades at a EV/Sales of −0.3×. Over the past ten years it has ranged from −5.2× (December 2018) to 188× (July 2021); the current reading is higher than 16% of that period. That is below the Biotechnology industry median of 9.6× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.6× | (53.76%) |
| FY2024 | 1.3× | (92.02%) |
| FY2023 | 16.2× | 275.50% |
| FY2022 | 4.3× | (91.11%) |
| FY2021 | 48.5× | (52.90%) |
| FY2020 | 103× | 312.74% |
| FY2019 | 25.0× | — |
| FY2018 | −4.5× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −0.1× | — |
| Mar 2026 | 0.7× | 21.57% |
| Dec 2025 | 0.6× | — |
| Sep 2025 | −0.5× | — |
| 31 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ARVN Arvinas, Inc. | −0.3× |
| MPLT MapLight Therapeutics, Inc. compare | n/m |
| EPRX Eupraxia Pharmaceuticals Inc. compare | n/m |
| CTNM Contineum Therapeutics, Inc. compare | n/m |
| AUTL Autolus Therapeutics PLC Sponsored ADR compare | 2.9× |
| ALLO Allogene Therapeutics, Inc. compare | 27.9× |
| OVID Ovid Therapeutics compare | 47.1× |
| OCS Oculis Holding AG compare | 133× |
| ALT Altimmune, Inc. compare | 3,985× |
| Biotechnology industry median | 9.6× |
| Healthcare sector median | 3.5× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)